R
Ray Borrow
Researcher at Manchester Royal Infirmary
Publications - 40
Citations - 2927
Ray Borrow is an academic researcher from Manchester Royal Infirmary. The author has contributed to research in topics: Vaccination & Meningococcal vaccine. The author has an hindex of 23, co-authored 40 publications receiving 2469 citations. Previous affiliations of Ray Borrow include Public Health England & University of Manchester.
Papers
More filters
Journal ArticleDOI
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment
Ulrich Vogel,Muhamed-Kheir Taha,Julio A. Vázquez,Jamie Findlow,Heike Claus,Paola Stefanelli,Dominique A. Caugant,Paula Kriz,Raquel Abad,Stefania Bambini,Anna Carannante,Ala Eddine Deghmane,Cecilia Fazio,Matthias Frosch,Giacomo Frosi,Stefanie Gilchrist,Marzia Monica Giuliani,Eva Hong,Morgan Ledroit,Pietro Giorgio Lovaglio,Jay Lucidarme,Martin Musilek,Alessandro Muzzi,Jan Oksnes,Fabio Rigat,Luca Orlandi,Maria Stella,Danielle Thompson,Mariagrazia Pizza,Rino Rappuoli,Davide Serruto,Maurizio Comanducci,Giuseppe Boccadifuoco,John J. Donnelly,Duccio Medini,Ray Borrow +35 more
TL;DR: MATS analysis showed that a multicomponent vaccine could protect against a substantial proportion of invasive MenB strains isolated in Europe, however, monitoring of antigen expression will be needed in the future.
Journal ArticleDOI
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection.
Jianmin Zuo,Alexander C Dowell,Hayden Pearce,Kriti Verma,Heather M. Long,Jusnara Begum,Felicity Aiano,Zahin Amin-Chowdhury,Bassam Hallis,Lorrain Stapley,Ray Borrow,Ezra Linley,Shazaad Ahmad,Ben Parker,Alex Horsley,Gayatri Amirthalingam,Kevin E. Brown,Mary Ramsay,Shamez N Ladhani,Paul Moss +19 more
TL;DR: In this article, the authors analyzed the magnitude and phenotype of the SARS-CoV-2-specific T cell response in 100 donors at 6 months following infection and found that the severity of primary infection establishes a'set point' for cellular immunity.
Journal ArticleDOI
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial
Robert C. Read,David Baxter,David Chadwick,Saul N. Faust,Saul N. Faust,Adam Finn,Stephen B. Gordon,Paul T. Heath,David J. M. Lewis,Andrew J. Pollard,David P. J. Turner,Rohit Bazaz,Amitava Ganguli,Tom Havelock,Tom Havelock,Keith R. Neal,Ifeanyichukwu O Okike,Begonia Morales-Aza,Kamlesh Patel,Matthew D. Snape,John Williams,Stefanie Gilchrist,Steve J. Gray,Martin C. J. Maiden,Daniela Toneatto,Huajun Wang,Maggie McCarthy,Peter M. Dull,Ray Borrow,Ray Borrow +29 more
TL;DR: Although there was no significant difference between groups at 1 month after vaccine course, MenACWY-CRM and 4CMenB vaccines reduced meningococcal carriage rates during 12 months after vaccination and therefore might affect transmission when widely implemented.
Journal ArticleDOI
Advances in the development of vaccines against Neisseria meningitidis.
TL;DR: This review highlights the evolution of meningococcal vaccines in general and discusses strategies being used to overcome the barriers to developing vaccines against NMB.
Journal ArticleDOI
Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity
TL;DR: Modeling suggested that protection against carriage persists for at least 3 years and predicted the stabilization of serogroup C disease at low levels (fewer than 50 cases per year) up to 2015-2016.